Zacks Investment Research upgraded shares of Aethlon Medical (AEMD) from NEUTRAL to OUTPERFORM on November 12, 2014, with a target price of $0.45.
AEMD's novel blood filtration device could have utility in the treatment of Hepatitis-C, HIV, sepsis, cancer, pandemic diseases and bioterror applications. AEMD just got FDA and IRB approvals to run a human study in HCV which is a major milestone. Study to commence in near term. DARPA contracts have provided revenue/cash while also providing credibility of the technology and potentially facilitating the quest towards regulatory approval and commercialization. Mgmt has been very resilient and successful in pursuing high potential opportunities in other areas including Ebola, cancer, Alzheimer's and CTE. First Ebola patient treated with Hemopurifier has recovered. While we have had significant concerns about risks such as a previously shaky balance sheet and reliance on a single target market, AEMD's substantive progress in allaying these concerns prompted our upgrade in recommendation from Neutral to Outperform.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Aethlon Medical (AEMD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment